Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Предстоящие клинические испытания
-
Zheng LiЕще не набираютКогнитивная слабость
-
Techpool Bio-Pharma Co., Ltd.Еще не набирают
-
Istanbul University - CerrahpasaРекрутингЦеребральный параличТурция (Туркие)
-
Project Skin MDЕще не набирают
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Еще не набираютОстрый ишемический инсульт ОИС
-
Hospital Universitario La PazЕще не набираютЗаложенность носа | Бронхиолит | Острые инфекции верхних дыхательных путейИспания
-
E-DA HospitalNational Cheng Kung University; Metal Industries Research & Development Centre (MIRDC)РекрутингОбструктивное апноэ снаТайвань
-
Assistance Publique - Hôpitaux de ParisЕще не набираютОсложнение экстракорпоральной мембранной оксигенации | ECMO Cannula InfectionФранция
-
Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.РекрутингРак молочной железы | Рак желудка | Рак яичников | Продвинутые солидные опухоли | Другие солидные опухолиКитай
-
Gustave Roussy, Cancer Campus, Grand ParisЕще не набираютAdult Carriers of a Pathogenic or Probably Pathogenic (Class 4 and 5) Germline Variation in the TP53 GeneФранция
-
Assistance Publique - Hôpitaux de ParisРекрутингСиндром дефицита вниманияФранция
-
University GhentЕще не набираютПослеоперационная боль, острая | Необратимый пульпит (зубная боль) | Pulp Necrosis, Apical PeriodontitisБельгия
Clinical Research Jobs
-
Italy - Milan
-
United States - Shrewsbury
-
United Kingdom - Leeds
-
India - Kochi
-
United States - Massachusetts - Boston
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China